Summary
Abuse potential refers to the likelihood for a drug to be used in nonmedical situations for its positive psychoactive effects. PRA Health Sciences’ Early Development Services group offers expert services to measure abuse potential of investigational drugs by performing human abuse liability (HAL) studies, which are required for drugs that affect the central nervous system, drugs similar to known drugs with abuse potential, and drugs with positive psychoactive effects. This poster discusses what a HAL study is and the challenges posed to study teams and medical writers by the complexity and unique design of these Phase I clinical trials.
Register to download
Human Abuse Liability Studies: Not Your Traditional Phase I Study
You may also be interested in:
Fact Sheet
CSF Sampling
PRA understands how cerebrospinal fluid (CSF) sampling benefits our clients’ early phase trials. We regularly conduct CSF sampling to collect key PK…
Poster
Pharmacokinetic Characteristics of Intranasal Administration of Oxycodone ARIR
Abuse of prescription opioids continues to be a serious public health concern, with as many as 12.5 million individuals aged 12 or older reporting…
Blog
Ask the Experts: What Do We Need to Know About ALZ and other Brain-Related Illnesses?
Many people have heard of brain-related illnesses such as Alzheimer’s (ALZ). In honor of Brain Awareness Month, we shed some light on ALZ and other…